fig1

Figure 1. IL-33 expression and outcome in PDAC. (A) Representative images showing differential expression (high vs. low) of IL-33 in cores of tissue microarrays including specimens from two PDAC patients^[24]. The immunohistochemical staining was performed using the IL-33 antibody AF3626 (R&D systems), as reported by Alam et al^[10]; (B) the mRNA expression of IL-33 in PDAC was evaluated using the web-based genomics analysis and visualization platform GEPIA, analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects, including 179 PDAC and 117 normal pancreatic tissues; (C) the levels of IL-33 mRNA expression did not correlate with overall survival in the TCGA-PAAD database.